目的 探討裸花紫珠顆粒聯(lián)合糠酸莫米松鼻噴霧劑治療變應(yīng)性鼻炎的臨床療效。方法 選擇2023年5月—2024年5月在青島市城陽(yáng)區(qū)人民醫(yī)院診治的變應(yīng)性鼻炎患者108例，依據(jù)隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各54例。對(duì)照組患者給予鼻噴糠酸莫米松鼻噴霧劑，每次每只鼻孔2撳，1次/d，癥狀明顯緩解后更改為每次每只鼻孔1撳，1次/d。治療組患者在對(duì)照組治療方案基礎(chǔ)上口服裸花紫珠顆粒，1袋/次，3次/d。兩組患者均接受4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者鼻伴隨癥狀總分表（TNNSS）和鼻炎生活質(zhì)量問(wèn)卷（RQLQ）評(píng)分，鼻腔分泌物骨膜蛋白（POSTN）、白細(xì)胞介素-13（IL-13）和嗜酸性細(xì)胞陽(yáng)離子蛋白（ECP）水平，以及3、6個(gè)月的復(fù)發(fā)率。結(jié)果 治療后，治療組總有效率（96.30%）明顯高于對(duì)照組（85.19%，P＜0.05）。治療后，兩組TNNSS評(píng)分和RQLQ評(píng)分較治療前明顯下降（P＜0.05），且治療組評(píng)分下降幅度顯著高于對(duì)照組（P＜0.05）。治療后，兩組患者鼻腔分泌物POSTN、IL-13和ECP水平較治療前明顯降低（P＜0.05），且治療組患者的下降幅度顯著高于對(duì)照組（P＜0.05）。治療組患者療程結(jié)束后3、6個(gè)月的復(fù)發(fā)率明顯低于對(duì)照組（P＜0.05）。結(jié)論 裸花紫珠顆粒聯(lián)合糠酸莫米松鼻噴霧劑治療變應(yīng)性鼻炎療效顯著，不僅能夠顯著降低鼻腔分泌物相關(guān)指標(biāo)水平和復(fù)發(fā)率，而且能改善患者鼻部癥狀和生活質(zhì)量。

Objective To explore the clinical efficacy of Luohua Zizhu Granules combined with mometasone furoate aqueous in treatment of allergic rhinitis. Methods Patients (108 cases) with allergic rhinitis in Chengyang District People's Hospital from May 2023 to May 2024 were divided into control and treatment group according to random number table method, and each group had 54 cases. Patients in the control group were administered with Mometasone Furoate Aqueous Nasal Spray, 2 presses for each nostril once, and changed to 1 press for each nostril once after symptoms were significantly relieved, once daily. Patients in the treatment group were po administered with Luohua Zizhu Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, and the scores of TNNSS and RQLQ, the levels of POSTN, IL-13 and ECP of nasal secretions, the recurrence rates of 3 and 6 months after treatment in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group (96.30%) was significantly higher than that in the control group (85.19%, P < 0.05). After treatment, the TNNSS score and RQLQ score in two groups were significantly decreased compared with before treatment (P < 0.05), and the scores decrease in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of POSTN, IL-13 and ECP of nasal secretions in two groups were significantly lower than those before treatment (P < 0.05), and the decrease in the treatment group was significantly higher than that in the control group (P < 0.05). The recurrence rates at 3 and 6 months after the end of the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The combination therapy of Luohua Zizhu Granules and mometasone furoate aqueous for allergic rhinitis is significantly effective, not only significantly reducing the levels of nasal secretion-related indicators and recurrence rates, but also improving patients' nasal symptoms and quality of life.

R976

山東省醫(yī)藥衛(wèi)生科技發(fā)展計(jì)劃項(xiàng)目（2022WS0059）